相似文献
1
Comparative in vitro susceptibilities and bactericidal activities of investigational fluoroquinolone ABT-492 and other antimicrobial agents against human mycoplasmas and ureaplasmas.
Antimicrob Agents Chemother. 2003 Dec;47(12):3973-5. doi: 10.1128/AAC.47.12.3973-3975.2003.
2
Comparative in vitro activities of the investigational fluoroquinolone DC-159a and other antimicrobial agents against human mycoplasmas and ureaplasmas.
Antimicrob Agents Chemother. 2008 Oct;52(10):3776-8. doi: 10.1128/AAC.00849-08. Epub 2008 Jul 28.
3
Comparative in vitro activities of investigational peptide deformylase inhibitor NVP LBM-415 and other agents against human mycoplasmas and ureaplasmas.
Antimicrob Agents Chemother. 2005 Jun;49(6):2541-2. doi: 10.1128/AAC.49.6.2541-2542.2005.
4
Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101.
Antimicrob Agents Chemother. 2009 May;53(5):2139-41. doi: 10.1128/AAC.00090-09. Epub 2009 Mar 2.
5
In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmas.
Antimicrob Agents Chemother. 2003 Jan;47(1):161-5. doi: 10.1128/AAC.47.1.161-165.2003.
6
In vitro activities of ABT-773 and other antimicrobials against human mycoplasmas.
Antimicrob Agents Chemother. 2003 Jan;47(1):39-42. doi: 10.1128/AAC.47.1.39-42.2003.
7
Comparative in vitro activity of azithromycin, clarithromycin, erythromycin and lomefloxacin against Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum.
Eur J Clin Microbiol Infect Dis. 1990 Nov;9(11):838-41. doi: 10.1007/BF01967388.
8
Activities of the Benzoquinolizine Fluoroquinolone Levonadifloxacin (WCK 771) and Other Antimicrobial Agents against Mycoplasmas and Ureaplasmas in Humans, Including Isolates with Defined Resistance Mechanisms.
Antimicrob Agents Chemother. 2018 Oct 24;62(11). doi: 10.1128/AAC.01348-18. Print 2018 Nov.
9
In vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to sparfloxacin and PD 127391.
Antimicrob Agents Chemother. 1991 Jun;35(6):1181-5. doi: 10.1128/AAC.35.6.1181.
10
Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to a new quinolone, OPC 17116.
Antimicrob Agents Chemother. 1993 Aug;37(8):1726-7. doi: 10.1128/AAC.37.8.1726.
引用本文的文献
1
Strategic re-engineering of antibiotics.
Nat Rev Bioeng. 2025 Mar;3(3):213-229. doi: 10.1038/s44222-024-00250-w. Epub 2024 Oct 15.
2
Updated Review on Clinically-Relevant Properties of Delafloxacin.
Antibiotics (Basel). 2023 Jul 28;12(8):1241. doi: 10.3390/antibiotics12081241.
3
Activity of Delafloxacin and Finafloxacin against Mycoplasma hominis and Species.
Microbiol Spectr. 2022 Jun 29;10(3):e0009922. doi: 10.1128/spectrum.00099-22. Epub 2022 May 9.
4
Delafloxacin, Finafloxacin, and Zabofloxacin: Novel Fluoroquinolones in the Antibiotic Pipeline.
Antibiotics (Basel). 2021 Dec 8;10(12):1506. doi: 10.3390/antibiotics10121506.
5
Clinical Pharmacokinetics and Pharmacodynamics of Delafloxacin.
Eur J Drug Metab Pharmacokinet. 2019 Jun;44(3):305-317. doi: 10.1007/s13318-018-0520-8.
6
Delafloxacin Broth Microdilution and Disk Diffusion Antimicrobial Susceptibility Testing Guidelines: Susceptibility Breakpoint Criteria and Quality Control Ranges for an Expanded-Spectrum Anionic Fluoroquinolone.
J Clin Microbiol. 2018 Jul 26;56(8). doi: 10.1128/JCM.00339-18. Print 2018 Aug.
7
Emerging treatment options for acute bacterial skin and skin structure infections: focus on intravenous delafloxacin.
Infect Drug Resist. 2018 Apr 4;11:479-488. doi: 10.2147/IDR.S142140. eCollection 2018.
8
New Horizons in Mycoplasma genitalium Treatment.
J Infect Dis. 2017 Jul 15;216(suppl_2):S412-S419. doi: 10.1093/infdis/jix132.
9
Activity of Delafloxacin and Microbiological Response against Fluoroquinolone-Susceptible and Nonsusceptible Staphylococcus aureus Isolates from Two Phase 3 Studies of Acute Bacterial Skin and Skin Structure Infections.
Antimicrob Agents Chemother. 2017 Aug 24;61(9). doi: 10.1128/AAC.00772-17. Print 2017 Sep.
10
Delafloxacin: design, development and potential place in therapy.
Drug Des Devel Ther. 2017 Mar 20;11:881-891. doi: 10.2147/DDDT.S106071. eCollection 2017.
本文引用的文献
1
In vitro activities of ABT-492, a new fluoroquinolone, against 155 aerobic and 171 anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis.
Antimicrob Agents Chemother. 2003 Sep;47(9):3008-11. doi: 10.1128/AAC.47.9.3008-3011.2003.
2
Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002.
Antimicrob Agents Chemother. 2003 Jun;47(6):1875-81. doi: 10.1128/AAC.47.6.1875-1881.2003.
3
Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002.
Antimicrob Agents Chemother. 2003 Jun;47(6):1867-74. doi: 10.1128/AAC.47.6.1867-1874.2003.
4
In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmas.
Antimicrob Agents Chemother. 2003 Jan;47(1):161-5. doi: 10.1128/AAC.47.1.161-165.2003.
5
Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones.
Antimicrob Agents Chemother. 2001 Sep;45(9):2604-8. doi: 10.1128/AAC.45.9.2604-2608.2001.
6
In vitro activities of moxifloxacin and other fluoroquinolones against Mycoplasma pneumoniae.
Antimicrob Agents Chemother. 2001 Jun;45(6):1908-10. doi: 10.1128/AAC.45.6.1908-1910.2001.
7
Comparative activities of telithromycin (HMR 3647), levofloxacin, and other antimicrobial agents against human mycoplasmas.
Antimicrob Agents Chemother. 2000 Jul;44(7):1980-2. doi: 10.1128/AAC.44.7.1980-1982.2000.
8
In vitro susceptibilities of Mycoplasma hominis to six fluoroquinolones as determined by E test.
Antimicrob Agents Chemother. 1999 Oct;43(10):2571-3. doi: 10.1128/AAC.43.10.2571.
9
In vitro activity of BAY 12-8039, a new fluoroquinolone against mycoplasmas.
Antimicrob Agents Chemother. 1998 Mar;42(3):703-4. doi: 10.1128/AAC.42.3.703.
10
Susceptibilities of genital mycoplasmas to the newer quinolones as determined by the agar dilution method.
Antimicrob Agents Chemother. 1989 Jan;33(1):103-7. doi: 10.1128/AAC.33.1.103.
Zotero 插件